for aspirin and placebo, respectively; P 48 augments the sensitivity of carotid baroreflex control of heart rate during concurrent muscle 57 mechanoreflex and metaboreflex activation in healthy older humans. This finding furthers 58 our understanding of how low-dose aspirin can affect cardiovascular control in humans. 59 been shown to be lower in older compared to young subjects, at rest as well as during 69 exercise (4, 15). Older subjects also exhibit a smaller and delayed HR decrease in response 70 to carotid baroreceptor activation at rest compared to young subjects (14) . These findings 71 suggest that advancing age is linked with reduced cardiac baroreflex sensitivity during 72 exercise, which is likely due to the age-related decrease in cardiac vagal activity at rest in 73 older people. 74
The exercise pressor reflex, in addition to the arterial baroreflex and central 75 command, generates the BP increase required in response to exercise (30). The contribution 76 of the muscle mechanoreflex component of the exercise pressor reflex, involving 77 stimulation of mechanically sensitive receptors on muscle afferent nerve fibers (23, 24) , has 78 been investigated in humans (2, 13, 16) and animals (19, 32, 42) , and its role in modulating 79 baroreflex function in humans has received some attention (22) . Passive calf muscle stretch, 80 likely stimulating some of the same mechanoreceptors that are activated during muscular 81 contraction (20), decreases spontaneous cardiac baroreflex sensitivity in humans (8). As 82 stimulation of muscle mechanosensitive receptors feeds back along group III afferent fibers 83 and integrates as an inhibitory input with excitatory feedback from baroreceptive afferents 84 at the level of the nucleus tractus solitarii (NTS) in the medulla oblongata (38, 39) , this 85 decrease is likely via inhibition of cardiac vagal activity (16, 17) . Passive calf stretch in 86 humans also decreases the maximal sensitivity of CBR-HR control, but not CBR-mean 87 arterial BP (CBR-MAP) control, when there is concurrent local metabolite accumulation 88 (8). As there are receptors on muscle afferent fibers that have polymodal properties and are 89 sensitive to both mechanical and metabolic stimuli (25), it appears that metabolite 90 sensitization of mechanosensitive receptors increases their inhibitory feedback to the NTS, 91 resulting in further decreases in cardiac vagal outflow. 92
Thromboxane A 2 (TXA 2 ) is one of several metabolites produced by skeletal muscle 93 during exercise (40). A TXA 2 mimetic has been shown to stimulate group III and IV 94 afferents in anesthetized cats (26). Low-dose aspirin (<100 mg) preferentially inhibits the 95 cyclooxygenase-1 isoenzyme that breaks down arachidonic acid to TXA 2 without blocking 96 prostaglandin production (3, 35) . We recently showed that inhibiting thromboxane 97 production with low-dose aspirin augmented the maximal and operating point sensitivities 98
of CBR-HR control during passive calf stretch with concurrent local metabolite 99 accumulation in healthy young subjects, without affecting CBR-MAP control (10). This 100 increased sensitivity of CBR-HR control appears linked to reduced thromboxane 101 sensitization of muscle mechanosensitive receptors, resulting in decreased cardiac vagal 102 inhibition. However, whether a similar aspirin-induced augmentation in CBR-HRspecifically designed Leg Exercise And Passive Stretch (LEAPS) system. The right leg was 126 flexed by 30 o with the lower leg positioned parallel to the ground, and the foot strapped to 127 the footplate to minimize heel lift during calf exercise and passive stretch. Before 128 performing the trials, the range of passive dorsiflexion of the ankle joint was assessed by 129 pivoting the footplate as far as was comfortable, which would subsequently be applied 130 during passive calf stretch. Maximal voluntary contraction (MVC) of the calf plantarflexor 131 muscles was assessed by recording the maximal torque produced when subjects briefly 132 pushed as hard as possible against the footplate. This was repeated 3-5 times, with each 133 effort separated by 1 min and the largest torque taken to indicate subjects' MVC. 70% of 134 each subject's MVC was calculated and set on a torque display box in front of the subject 135 so they could visualize the level of torque produced during the exercise phase in the 70% 136 MVC trial. We have previously found that performance of 70% MVC calf exercise for 1.5 137 minutes is sufficient for metabolites to be produced that can then be trapped within the 138 lower limb circulation during CO following exercise, based on MAP remaining elevated 139 above baseline levels at this time (10). 140
Subjects were habituated to the experimental protocol and procedures during a 141 familiarization visit. Subjects attended two further experimental visits, in which they 142 performed two trials during both visits. Visits were preceded by either 7 days of low-dose 143 aspirin (81 mg) or placebo, and were separated by at least 4 weeks to allow for washout of 144 aspirin in between visits and to remain consistent with our previous work in healthy young 145 subjects (10). The order of these visits was counterbalanced, as was the order of the twotrials within each visit. A schematic diagram of the experimental protocol for these trials is 147 shown in Figure 1 . After subjects were settled for at least 10 min, the trial began with a 5 148 min baseline phase. During this time, blood samples were taken to measure baseline 149 thromboxane B 2 (TXB 2 ) and 6-keto prostaglandin F 1α (PGF 1α ) levels. Subjects then either 150 continued to rest (0% MVC trial) or performed isometric right calf exercise at 70% MVC 151 for 1.5 min (70% MVC trial). Five seconds before the end of exercise, a cuff around the 152 right thigh was inflated to 250mmHg to occlude blood flow and trap metabolites produced 153 during exercise within the lower leg. This circulatory occlusion (CO) remained for 7.5 min. 154
Three-and-a-half min into CO, the right calf muscle was passively stretched by pivoting the 155 footplate to the pre-set level, which was maintained for 3 min (CO+stretch). The foot was 156 then returned to its original position and after a further minute of CO, the thigh cuff was 157 deflated. This was followed by a 2 min recovery phase. Therefore, these two trials included 158 phases of muscle mechanoreflex activation (0% MVC trial) or concurrent muscle 159 mechanoreflex and metaboreflex activation (70% MVC trial) during passive calf muscle 160
stretch. 161
Cardiovascular and experimental measurements. R-R interval was measured using 162 a 3-lead electrocardiogram (ECG; Cardiocap/5, GE Healthcare, Waukesha, WI, USA), 163 from which HR was derived. Beat-to-beat MAP was measured using a finger cuff 164 (Finometer, FMS, Arnhem, Netherlands) and was calibrated to baseline MAP 165 measurements taken in triplicate using an arm cuff (Philips SureSigns VS3, Andover, MA, 166 USA) before each trial. Respiratory movements were measured using a pneumography belt 167 placed around the abdomen. Torque levels produced during calf exercise and passivestretch were measured using a load cell on the footplate. The pressure generated in the neckcollar (see 'Carotid baroreflex assessment') was measured by a transducer fitted to the front 170 of the collar. An analogue-to-digital converter (Cambridge Electronic Design 1401plus, 171 CED, Cambridge, UK) was used to sample ECG, Finometer, pneumograph, torque and 172 neck collar pressure signals at 1000 Hz. Data were recorded and displayed using Spike2 173 software (CED, Cambridge, UK), which was used for off-line analysis. 174
Carotid baroreflex assessment. Carotid baroreflex control of HR and MAP was 175 assessed using a variable pressure neck chamber, where a range of positive and negative 176 pressures were applied via a rubber-lined malleable collar that was secured around the front 177 two-thirds of the neck with a Velcro strap (1, 9, 12, 37) . A rapid series of 12 computer-178 controlled pressures lasting 500 ms each were produced by a vacuum and delivered through 179 the collar. These pressures were triggered off consecutive R waves, each delayed 50 ms 180 after the R wave. Pressures were in the order +40, +40, +40, +40, +20, +10, 0, -10, -20, -40, 181 -60 and -80 mmHg, and occurred during an end-expiratory breath-hold lasting around 10 s. 182
Neck pressures were applied three times during the rest and stretch phases of the protocol, 183 with at least 1 min rest between each series. experimental visits, subjects took a 7-day course of either low-dose aspirin (81 mg) or 214 placebo (sucrose capsules). We have shown previously that this low-dose aspirin treatment 215 significantly decreases TXB 2 by 84 ± 4% but does not affect PGF 1α levels in healthy young 216 humans (10). Subjects were instructed to take one capsule each morning, with their last 217 dose being taken on the day before their visit. They were also asked not to take any aspirin 218 or other non-steroidal anti-inflammatory drugs other than the treatment we provided them 219 in the two weeks preceding each of their two experimental visits (10, 21, 36) . Three 220 subjects reported taking low-dose aspirin voluntarily before being enrolled in this study. 221
These three subjects were asked to stop taking aspirin in this way 2 weeks prior to 222 participating in this study to allow for washout of aspirin. Seven-day treatment of 81mg 223 aspirin has been shown to irreversibly inhibit platelet production of TXA 2 . Around 10% of 224 platelets are newly formed every day so once aspirin treatment is stopped, it takes 225 approximately 10 days for 100% of platelets to function normally (3, 35). They were 226 instructed to then take the low-dose aspirin and placebo treatments for this study in the 227 same manner as the other subjects.that causes TXA 2 production without inhibiting prostaglandin production (3, 35). TXA 2 is 230 rapidly (within approximately 30 s) hydrolyzed to TXB 2 in the blood so is difficult to 231 measure. Therefore, measuring TXB 2 levels is the standard method for assessing 232 cyclooxygenase blockade (5), and was used to assess the effectiveness of the aspirin 233 treatment. PGF 1α was measured to further assess the efficacy of the low-dose aspirin 234 treatment to block TXA 2 but not prostaglandin production. An intravenous catheter was 235 placed into a vein at the antecubital fossa of one arm to draw blood samples to measure 236 baseline plasma TXB 2 and PGF 1α levels. TXB 2 and PGF 1α levels were measured using 237 enzyme immunoassay kits (Cayman Chemical Company, Ann Arbor, MI, USA) in 8 238
subjects. 239
Data and statistical analyses. Raw data files were analyzed using custom-written 240 script files to produce beat-to-beat values for R-R interval, HR, systolic blood pressure, 241 diastolic blood pressure and MAP. Group means were calculated for each phase and each 242 trial. End-exercise values were calculated from the last 15 s of exercise. The first 30 s 243 following the end of exercise was excluded from data analysis so only steady state data was 244 included in the CO phase. Neck collar pressures were measured directly from raw data 245 files, and CBR function curves and their parameters were derived using Sigmaplot (Systat 246 Software Inc., San Jose, CA, USA). Each series of 12 pressures (three performed during 247 rest and three during stretch) was fitted to the regression model to produce a CBR function 248 curve for HR and MAP. If there were two or three curves that met the inclusion criteria for 249 the correlation coefficient of r 2 >0.95 within each phase, the parameters for these curveswere averaged. This produced average CBR-HR and CBR-MAP curves for both the rest 251 and stretch phases in each trial, which consisted of data from one, two or three pressure 252
series. 253
All values are expressed as mean ± SEM. Significant differences in exercise and 254 stretch parameters were identified using paired-samples t-tests and two-way repeated 255 measures analysis of variance (ANOVA), with within-subject factors including treatment 256 and trial. Significant differences in TXB 2 and PGF 1α levels were identified using paired-257 samples t-tests. Significant differences in cardiovascular and CBR variables were identified 258 using two-and three-way repeated measures ANOVA, with within-subject factors 259 including treatment, trial, and phase of trial. When significant interactions were found, 260 post-hoc analysis involving paired-samples t-tests with a Holm-Bonferroni correction was 261 performed. Statistical significance was set at P < 0.05 and all statistical analysis was 262 performed using SPSS (IBM, Armonk, NY, USA). 263
Additionally, CBR-HR G MAX and G OP during CO+stretch in the placebo 70% and 264 aspirin 70% trials were compared to the corresponding values measured in healthy young 265 subjects who undertook the same experimental interventions as in the current study, on 266 which we have previously published (10). The relative change from placebo with aspirin in 267 CBR-HR G MAX and G OP during CO+stretch in the placebo 70% and aspirin 70% trials was 268 also calculated for both Older and Young groups. Significant differences in these variables 269 were identified using two-way mixed repeated measures ANOVA, with a within-subject 270 factor of treatment and a between-subject factor of age, and independent t-tests. Post-hoc 271 analysis, statistical significance level, and statistical software used were the same as above.
are shown in Table 1 . MVCs were similar in the two 70% trials, as were torques produced 275 during 70% exercise. Range of motion of the right ankle was similar in all trials. Peak 276 torques within the first 5 s of stretch and torques at the end of stretch were similar in all 277 trials, as were their relative magnitudes compared to the corresponding MVC. 278 TXB 2 and PGF 1α . Baseline TXB 2 levels following low-dose aspirin treatment were 279 significantly lower compared to following placebo treatment (P < 0.05; Figure 2A) , with a 280 reduction of 83 ± 4%. PGF 1α levels were similar following low-dose aspirin and placebo 281 treatments ( Figure 2B ). The intra-assay coefficient of variation for TXB 2 was 23 ± 4% and 282 for PGF 1α was 21 ± 5%. 283 Cardiovascular variables. Baseline HR and blood pressures are shown in Table 2 . 284
Baseline HR was lower following the low-dose aspirin treatment (P < 0.05). Baseline 285 MAP, systolic and diastolic blood pressures were similar in all trials. HR responses during 286 all four trials are shown in Figure 3A . 70% exercise significantly increased HR (P < 0.05), 287 and this increase was similar with placebo and aspirin. Following the end of exercise, HR 288 fell but remained elevated above baseline during CO (P < 0.05). Stretch increased HR from 289 CO levels by a similar magnitude in all trials (P < 0.05). HR was not significantly different 290 between placebo and aspirin trials during CO+stretch. HR remained above baseline during 291 CO after stretch and recovery. MAP responses during all four trials are shown in Figure 3B . 292 70% exercise significantly increased MAP (P < 0.05), and this increase was similar withplacebo and aspirin. Following the end of exercise, MAP fell but remained elevated above 294 baseline during CO (P < 0.05). MAP continued to be raised above baseline during stretch, 295 with no significant difference in MAP between placebo and aspirin trials. MAP then 296 returned to baseline when circulatory occlusion ended. 297
CBR control of HR. Logistic model parameters and derived variables describing 298
CBR-HR control during rest and CO+stretch in all four trials are shown in Tables 3 and 4 , 299 respectively. Stimulus-response function curves for CBR-HR during rest and CO+stretch in 300 placebo 70% and aspirin 70% are shown in Figure 4 . Compared to rest, stretch during CO 301 significantly increased OP and reset CBR-HR curves upward and rightward in all trials, as 302 illustrated by the increases in A 3 , A 4 , threshold, and saturation (P < 0.05). In the 70% trials, 303 both G MAX and G OP were significantly greater in stretch during CO with aspirin compared 304 to placebo (P < 0.05; Figures 5A and 5B, respectively). 305
CBR control of MAP. Logistic model parameters and derived variables describing 306
CBR-MAP control during rest and CO+stretch in all four trials are shown in Tables 5 and  307 6, respectively. Stimulus-response function curves for CBR-MAP during rest and 308 CO+stretch in placebo 70% and aspirin 70% are shown in Figure 6 . Compared to rest, 309 stretch during CO significantly increased OP and reset CBR-MAP curves upward and 310 rightward in all trials, as illustrated by the increases in A 3 , A 4 , threshold, and saturation (P 311 < 0.05). Both G MAX and G OP were similar during stretch with CO in all trials. 312
Comparison with young subjects. Figure 7 illustrates the CBR-HR G MAX and G OP 313 during CO+stretch in the placebo 70% and aspirin 70% trials for the older subjects and thecohort of young subjects whose data we have previously published (10). The older group 315 had a significantly lower CBR-HR G MAX and G OP compared to the young group across both 316 aspirin and placebo in the 70% trials (P < 0.05; Figures 7A and 7C, respectively) . CBR-HR 317 G MAX and G OP were significantly greater with aspirin compared to placebo in stretch during 318 CO in the 70% trials in both the older and young groups (P < 0.05; Figures 7A and 7C,  319 respectively). This increase in CBR-HR G MAX with aspirin in stretch during CO in the 70% 320 trials was smaller in the older compared to the young group (P < 0.05; Figure 7A) . 321
However, when expressed as a relative change from placebo with aspirin, the increase in 322 both CBR-HR G MAX and G OP with aspirin in stretch during CO in the 70% trials was 323 similar in the older and young groups ( Figures 7B and 7D, respectively) . 324
DISCUSSION

325
The main finding from this study was that low-dose aspirin augmented the maximal 326 and operating point sensitivities of CBR-HR control during passive calf muscle stretch with 327 concurrent local metabolite accumulation in healthy older humans. This aspirin-induced 328 increase in sensitivity of CBR-HR, but not CBR-MAP, control appears linked to reduced 329 thromboxane sensitization of muscle mechanosensitive receptors, resulting in decreased 330 cardiac vagal inhibition. This effect of low-dose aspirin results in an enhanced ability of the 331 carotid baroreflex to alter cardiac vagal activity in response to a change in BP during 332 concurrent muscle mechanoreflex and metaboreflex activation, conditions that simulate 333 exercise. Additionally, this aspirin-induced increase in CBR-HR sensitivity during stretchwith concurrent metabolite accumulation appears similar to that which can occur in healthy 335 young subjects. 336
Low-dose aspirin augmented maximal and operating point sensitivities of CBR-HR 337 control only when the muscle mechanoreflex and metaboreflex were both activated in these 338 healthy older subjects. We have shown previously that passive calf stretch in the presence 339 of local metabolite accumulation decreases spontaneous cardiac baroreflex sensitivity (8) 340 and maximal sensitivity of CBR-HR control (9) in healthy young humans. Metabolite 341 sensitization of muscle mechanosensitive receptors likely increases their inhibitory 342 feedback to the NTS, resulting in reduced cardiac vagal outflow and consequent decreased 343 cardiac baroreflex sensitivity. Following on from this, we showed that low-dose aspirin 344 augments maximal and operating point sensitivities of CBR-HR control during passive 345 stretch with local metabolite accumulation in healthy young humans (10). This finding 346 suggested that inhibition of thromboxane production via aspirin reduced the level of 347 metabolite sensitization of muscle mechanosensitive receptors, decreasing the inhibitory 348 feedback to the NTS, and resulting in an augmentation in cardiac vagal outflow in response 349 to an acute change in blood pressure. Findings from the present study suggest that low-dose 350 aspirin likely had a similar effect of reducing thromboxane sensitization of muscle 351 mechanosensitive receptors, leading to less inhibitory feedback to the NTS, and a resultant 352 augmentation in maximal and operating point sensitivities of CBR-HR control in healthy 353 older humans. Indeed, when we compared our current findings in older people with those 354 from young people on which we have previously published (10), we found that aspirin had 355 a similar relative effect of increasing CBR-HR sensitivity during passive stretch with localmetabolite accumulation in both older and young subjects. Therefore, it appears that despite 357 older people having lower maximal and operating point sensitivities and responding range 358 of CBR-HR control, indicating lower cardiac vagal activity, than young people (15), 359 cardiac vagal outflow can still be augmented in older people in response to an acute change 360 in BP during mechanical and metabolic stimulation of skeletal muscle, like in exercise, due 361 to the effect of low-dose aspirin. 362
This apparent ability of low-dose aspirin to increase cardiac vagal activity in 363 response to a change in BP during concurrent muscle mechanoreflex and metaboreflex 364 activation in healthy older people is intriguing, as it could be clinically relevant. Millions of 365 older people take low-dose aspirin daily to reduce their risk of suffering a heart attack or 366 stroke due to its antithrombotic properties (36, 41). Decreased baroreflex sensitivity is 367 linked with a higher incidence of sudden cardiac death (28). Our findings suggest that 368 aspirin augments CBR-HR sensitivity through increased cardiac vagal activity in response 369 to a change in BP in older people when their muscle mechanoreflex and metaboreflex are 370 activated, simulating conditions of physical activity. As CBR-HR G MAX and G OP are both 371 expressed as the change in HR per unit change in MAP, this means that a greater level of 372 cardiac vagal outflow occurs in response to a given change in MAP at this time. This 373 greater CBR-HR G MAX and G OP with aspirin during muscle mechanoreflex and 374 metaboreflex activation ( Figure 5 ) would result in HR responses to a change in BP 375 occurring within a smaller range of BPs (Figure 4) . In other words, the necessary HR 376 response to a change in BP would occur within fewer mmHg of BP, suggesting improved 377 CBR-HR control that would maintain BP within a tighter BP range when an older personhas taken low-dose aspirin and their skeletal muscles are mechanically and metabolically 379 stimulated, like during exercise. As the proportion of people over 65 years of age in the 380 population continues to rise and the number of older people participating in physical 381 activities and sports is also increasing, the prevalence of physical activity-related sudden 382 cardiac death is likely to grow (7). Therefore, in addition to the known antithrombotic 383 effects of aspirin, this apparent effect of aspirin to increase baroreflex sensitivity during 384 muscle mechanoreflex and metaboreflex stimulation, could further reduce the likelihood of 385 an older person suffering an arrhythmic death during an acute coronary syndrome when 386 they are physically active. As the HR decrease in response to CBR activation is smaller and 387 delayed in older compared to young people at rest (14), likely due to decreased cardiac 388 vagal activity (43), enhancing cardiac vagal outflow in response to a change in BP and 389 therefore increasing baroreflex sensitivity during mechanical and metabolic stimulation of 390 skeletal muscle in older people could be functionally and potentially clinically beneficial. 391
Low-dose aspirin augmented maximal and operating point sensitivities of CBR-HR 392 control during concurrent muscle mechanoreflex and metaboreflex activation in these 393 healthy older subjects ( Figure 5A ) but did not affect the absolute HR at this time ( Figure  394 3A) or CBR-HR resetting (Figure 4) . This difference suggests that aspirin leads to an 395 increase in cardiac vagal activity specifically in response to an acute change in BP during 396 muscle mechanoreflex and metaboreflex activation, rather than affecting HR per se at this 397 time. This may be related to differing involvement of specific neural circuits within the 398 medulla oblongata, such as the NTS and nucleus ambiguous, that regulate parasympathetic 399 and sympathetic neural outflow to control HR and BP (38). As the augmentation inmaximal and operating point sensitivities of CBR-HR control only occurred when muscle 401 mechanoreflex and metaboreflex activation as well as low-dose aspirin treatment were 402 combined, rather than with aspirin treatment by itself, this suggests that reducing 403 thromboxane sensitization of muscle mechanosensitive receptors with aspirin results in 404 enhanced cardiac vagal activity in response to an acute change in BP. This effect of aspirin 405 during muscle mechanoreflex and metaboreflex activation appears to be specific to CBR-406 HR sensitivity, and not CBR-MAP control or overall HR or BP. 407
Pharmacological blockade of thromboxane receptors in the hindlimb of 408 decerebrated rats does not affect the HR increase in response to passive hindlimb stretch 409 (29). This is similar to our finding in older healthy humans, as well as young healthy 410
humans (10), that low-dose aspirin did not affect the HR increase in response to passive 411 calf muscle stretch ( Figure 3A) . However, pharmacological blockade of thromboxane 412 receptors in the hindlimb of decerebrated rats did attenuate the BP increase in response to 413 passive hindlimb stretch, as well as the HR and BP increases in response to static hindlimb 414 contraction (29). Interestingly, this thromboxane receptor blockade in decerebrated rats 415 with chronic femoral artery occlusion, an animal model of peripheral arterial disease, 416 reduced the BP and HR increases in response to both static hindlimb contraction and 417 passive hindlimb stretch (29). The main finding of the current study in healthy older 418 humans, as well as healthy young humans (10), suggests that reduced thromboxane 419 sensitization of muscle mechanosensitive receptors with aspirin leads to augmented cardiac 420 vagal activity in response to an acute change in BP. Collectively, these findings suggest that 421 thromboxane stimulation of receptors within skeletal muscle plays a role in the neuralregulation involved in generating the exercise pressor reflex. Thromboxane may be a 423 significant contributor to the augmented pressor response to exercise in peripheral arterial 424 disease, and warrants further study. 425
One study limitation is that three of the twelve older subjects reported taking low-426 dose aspirin before being enrolled in the study. They were not instructed to take aspirin by 427 their physician but chose to do so voluntarily. Although any carryover effects from them 428 previously taking low-dose aspirin cannot be ruled out, these subjects adhered to a 2-week 429 washout period prior to participating in the study to minimize any potential effects. Also, 430 the responses with aspirin and placebo during CO+stretch of these three older subjects were 431 similar compared to the other nine older subjects regarding CBR-HR G MAX and G OP (data 432 not shown). Therefore, it appears unlikely that previously taking low-dose aspirin in these 433 three subjects affected their results. 434
In conclusion, findings from this study suggest that low-dose aspirin augments the 435 
